論文の公開元へThe effects of methylglyoxal, a metabolite derived from glycolysis, on metabolic responses of adipocytes
概要
The rise of worldwide diabesity
There are currently more people who are obese than underweight globally [1]. Yet, the
total number of obese and severely obese people are projected to still increase across all
continents, especially in Europe, Latin America and Asia [1]. According to the latest statistics
provided by the World Obesity Atlas 2022 [2] which was published by the World Obesity
Federation, it is estimated that one in five women and one in seven men will be obese,
amounting to one billion obese people by 2030. Obesity is a significant risk factor for a number
of other non-communicable diseases such as type two diabetes (T2D), heart disease and cancer
[2]. Seeing that obesity has been thought to account for about 80–85% of the risk of developing
T2D, and that more than 90% of patients with T2D have a body mass index (BMI) ≥25.0 kg/m2
[3], it is undeniable that obesity is strongly associated with T2D, so much so that the term,
Diabesity, has been used to describe diabetes in the context of obesity [4].
Diabetes, a disease characterized by hyperglycaemia, is one of the top ten leading
causes of death in adults aged between 20 and 79 years old worldwide, corresponding to 12.2%
of global deaths from all causes in 2021, which amounts to up to 6.7 million deaths [5]. As of
2021, the International Diabetes Federation estimated that globally, there were 537 million
people, aged 20-79 years old with diabetes, and this number is projected to increase to 783
million by 2045 [5]. While global age-standardized rate of mortality and disability-adjusted
life-years (DALYs) for type one diabetes (T1D) has declined, total diabetes (including both
T1D and T2D) continues to increase, reflecting the fact that most of the global burden of
diabetes falls on T2D, which affects 90% of diabetic patients [6]. ...
この論文で使われている画像
